AI Agents for Clinical Trials: Fast, Effective, and Fully Compliant
How Evalion Health builds AI agents that accelerate drug development without cutting corners on reliability or compliance.
Clinical trials are how promising molecules become therapies that reach patients. The science is accelerating — AI-driven drug discovery is producing more candidates than ever. But the operational machinery that tests those candidates in humans? It’s still slow, expensive, and running on manual processes that break in predictable ways.
AI can fix this. Everyone in the industry knows it. Every sponsor has a deck about it. And yet, most clinical AI never makes it past the pilot stage.
The reason isn’t technical. It’s trust.
Clinical trials operate under some of the strictest regulatory standards in any industry — GCP, 21 CFR Part 11, HIPAA, IRB oversight. Nobody has shown that AI agents can meet that bar reliably, at scale, and with the evidence to back it up.
That’s exactly what we built Evalion to answer. This article is about what it takes to build AI agents that meet the regulatory bar in clinical trials — and why getting that right is the key to making drug development faster and more accessible.
Clinical trials are governed by Good Clinical Practice (GCP) — the international standard that defines how trials must be conducted, monitored, and documented. The updated ICH E6(R3), finalized in 2025, explicitly addresses technology-enabled trial conduct for the first time: risk-based quality management, proportionate monitoring, and documented oversight systems. In parallel, the FDA and EMA jointly released AI-specific guiding principles in January 2026, signaling that regulatory expectations for clinical AI are tightening fast.
Evalion’s architecture was built to meet GCP requirements natively — not as an afterthought. Here’s what that looks like in practice.
What our agents do
Evalion’s agents handle the high-volume, repetitive tasks that consume the most time, money, and compliance risk in clinical trials. A few examples of the problems we’re solving:
Patient Pre-Screening
Today, research coordinators spend hours calling patients, working through eligibility criteria, and scheduling follow-ups — while juggling multiple active trials. When follow-up takes more than 24 hours, enrollment probability drops 68%. Our pre-screening agent conducts the full eligibility conversation using an IRB-approved script, captures structured per-criterion determinations, and books qualified patients for a site visit — in a single interaction, with a complete audit trail.
Patient Engagement
Roughly 20% of enrolled patients drop out before a trial completes, and replacing each one costs approximately 3x the initial recruitment investment. Most dropout is preventable — missed visit reminders, unanswered questions, declining engagement that nobody notices until it’s too late. Our engagement agent handles visit reminders, adherence check-ins, and early dropout risk detection, keeping patients on track between site visits.
CRA Monitoring
Clinical research associates visit sites periodically — typically every few weeks — to verify source data, review documentation, and flag deviations. In between visits, problems compound undetected. Our monitoring agent performs source data verification by matching EHR records against EDC entries field by field, generates visit reports, and flags protocol deviations — not during periodic visits, but around the clock, across every site.
How we make them reliable
AI agents are built on large language models, which are inherently probabilistic — they generate different outputs for the same input, they can drift off-topic, and they have no built-in concept of “you must ask this question next.” In clinical trials, that’s not a quirk. It’s a disqualifier. A pre-screening agent that skips an exclusion criterion or a monitoring agent that misses a required data check isn’t just unreliable — it’s a regulatory violation.
Making these systems behave deterministically — consistently, verifiably, every time — is what the reliability layer is for. It’s not a single technique. It’s four interlocking layers, each catching what the others miss.
BUILD · Structured Agent Design
We encode every agent’s operational logic as a deterministic structure that defines exactly what steps must be taken and in what order. For conversational agents — like pre-screening or patient engagement — this means a finite state machine where the agent literally cannot skip a required question or drift off-script, while still generating natural, empathetic speech. For data-processing agents — like CRA monitoring or compliance validation — this means structured workflows that enforce every required check before producing an output. The LLM handles language. The architecture handles protocol adherence.
GCP — Protocol adherence is non-negotiable. GCP requires that trials are conducted in strict compliance with the approved protocol. Evalion’s deterministic architecture enforces this structurally — every agent decision is traceable, not a black box that happens to produce good outputs.
TEST · Continuous Evaluation
Before any agent goes live, it faces a battery of automated stress tests matched to its function. A pre-screening agent is tested against thousands of simulated patient conversations — including edge cases, adversarial inputs, and ambiguous answers. A CRA monitoring agent is tested against known data quality scenarios — missing fields, inconsistent entries, protocol deviations that should be caught. Every dimension is evaluated: protocol adherence, medical accuracy, tone, regulatory compliance. And this isn’t a one-time QA pass — every change to prompts, knowledge bases, or underlying models triggers full regression testing.
GCP — Quality management must be ongoing, not one-time. ICH E6(R3) requires risk-based quality management systems that operate throughout the trial lifecycle — proportionate monitoring, not periodic spot checks. Our evaluation engine runs continuously across all agent types.
CORRECT · Real-time Guardrails
For conversational agents, a secondary monitoring layer watches every live interaction — checking for hallucinations, protocol violations, and unauthorized disclosures — and intervenes before the response reaches the patient. A compliance officer on every call, at scale, with zero latency.
For data-processing agents, the same principle applies differently: a CRA agent’s source data verification is cross-checked before it’s marked as confirmed, a compliance agent’s deviation assessment is validated before it’s surfaced to the sponsor. The guardrail layer ensures that no agent output — conversational or analytical — propagates downstream without validation.
GCP — Subject safety prevails over all other interests. GCP’s foundational principle is that the rights, safety, and well-being of trial subjects are the most important consideration. Evalion’s guardrail layer ensures no agent output reaches a patient or decision-maker without validation — by architecture, not by policy.
MONITOR · Evals with Human-in-the-Loop
Agents that pass testing and run behind guardrails still need ongoing oversight. In production, an LLM-as-a-judge evaluation layer scores every agent action — protocol adherence, accuracy, compliance — automatically flagging outputs that fall below confidence thresholds. Clinical reviewers then review flagged cases, catching what automated detection misses and feeding corrections back into the evaluation engine.
This is the feedback loop that makes the system compound: every deployment generates data that improves the next one. The longer an agent runs, the more reliable it becomes — not less.
GCP — Monitoring must verify that data is accurate, complete, and verifiable. GCP requires documented oversight to protect subjects and ensure data quality. Our HITL monitoring layer delivers this at scale — AI flags, humans verify, the system learns.
How we make them compliant
You can build a reliable agent, but if you can’t prove it’s reliable to a regulator, it doesn’t matter. And compliance evidence can’t be bolted on after the product ships — it has to be a structural property of how the system operates.
Evalion’s compliance platform operates across every agent and every interaction, organized around three functions:
Capture
Every trial interaction — whether performed by an agent or a human — is logged automatically: call audio, transcripts, structured metadata, EHR queries, screening decisions, scheduling confirmations, data entries, coordinator approvals. No manual entry. The audit trail isn’t a report generated after the fact — it’s a byproduct of how the system operates. Append-only, cryptographically verified, inspection-ready from the moment it happens.
GCP — All trial information must be recorded, handled, and stored to allow accurate reporting and verification. This is the basis of ALCOA+ data integrity. Evalion’s capture layer produces this evidence automatically — not as a manual documentation effort.
Validate
Every captured interaction is validated against the full regulatory stack — GCP/ICH E6(R3), 21 CFR Part 11, HIPAA, IRB requirements, and protocol-specific rules like I/E criteria and visit windows. Deviations trigger real-time alerts for human intervention. What CRAs do during periodic site visits, our compliance agents do around the clock.
Report
Real-time compliance dashboards give sponsors 24/7 trial visibility: enrollment progress, data quality metrics, protocol deviation rates, compliance scores per site. Inspection-ready audit packages for any patient, any site, or any interaction are available on demand, instantly. No prep-for-audit phase. No document scramble before an inspection.
Where this comes from
We didn’t start in clinical trials. Evalion began as an AI evaluation and reliability company, working with enterprise clients building AI agents in regulated industries — finance, healthcare, HR. Environments where agents needed to follow precise protocols, where errors had real consequences, and where regulators expected evidence.
Over years of helping these companies build and ship reliable AI agents to production, we developed the evaluation frameworks, testing infrastructure, and compliance architecture that became our core platform. We published research with Oxford and Pompeu Fabra on how to systematically measure and improve AI agent quality in regulated environments.
The insight from that work was simple: reliability and compliance aren’t features you add at the end. They’re an architecture you build from the ground up — control, evaluation, guardrails, and compliance as interlocking layers, each reinforcing the others.
Clinical trials turned out to be the highest-impact application of that insight. Screening, feasibility, site monitoring, data verification, compliance tracking, patient engagement — high-volume, compliance-intensive, protocol-driven tasks. Exactly where reliable AI agents deliver the most value — so we pointed the entire platform at that problem.
What this unlocks
Drug discovery is accelerating. The operational infrastructure hasn’t kept up — until now.
Consider a mid-size biotech running a Phase 2 obesity trial. Today, that company is looking at 6–10 months just to activate sites and start enrolling, $15–30M in total trial costs, and a CRA team that visits each site every few weeks hoping to catch problems before they become audit findings. The operational burden is so heavy that many promising therapies never make it to Phase 3 — not because the science failed, but because the sponsor ran out of runway waiting for enrollment to complete.
Now imagine the same trial with AI agents handling pre-screening, engagement, and monitoring. Sites activate faster because feasibility is based on verified EHR data, not self-reported estimates. Pre-screening happens in days instead of months because agents work around the clock. Compliance evidence is generated automatically, not assembled retroactively. The sponsor gets real-time visibility into enrollment and data quality across every site — not biweekly reports compiled by an overstretched project manager.
AI agents that compress enrollment timelines, reduce screen failures, automate site monitoring, and produce better compliance evidence than manual processes — those agents don’t just make existing trials more efficient. They bring down the cost and complexity enough that smaller biotech companies with promising therapies can actually afford to run them.
That’s what we’re building at Evalion. Faster, affordable, reliable, and fully compliant — not in spite of the regulatory bar, but because we built for it from day one.
More therapies reaching more patients, sooner. That’s what this is about.
Evalion Health is building compliance-first AI agents for clinical trial operations. We connect sponsors and sites on a single platform for faster, more reliable trials.